•
Dec 31, 2019

Exact Sciences Q4 2019 Earnings Report

Generated revenue of $295.6 million, including Screening revenue of $229M and Precision Oncology revenue of $66M.

Key Takeaways

Exact Sciences Corp. reported a strong fourth quarter with a total revenue of $295.6 million and a net income of $77.9 million. Screening revenue increased by 60%, and Precision Oncology revenue was $66.2 million. The company's adjusted EBITDA was $9.7 million.

Total revenue was $295.6 million.

Screening revenue was $229.4 million, an increase of 60 percent.

Precision Oncology revenue was $66.2 million for the period Nov. 8, 2019 through Dec. 31, 2019.

Net income was $77.9 million, or $0.54 per diluted share.

Total Revenue
$296M
Previous year: $143M
+106.7%
EPS
-$0.37
Previous year: -$0.44
-15.9%
Gross Margin
72%
Non-GAAP Gross Margin
76%
Adjusted EBITDA
$9.7M
Gross Profit
$213M
Cash and Equivalents
$177M
Free Cash Flow
-$69.5M
Total Assets
$3.51B

Exact Sciences

Exact Sciences

Exact Sciences Revenue by Segment

Forward Guidance

The Company anticipates revenue of $1.61-$1.645 billion during 2020, including Screening revenue of $1.125-$1.15 billion and Precision Oncology revenue of $485-$495 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income